MTOR and lung carcinoma: Moreover, this study suggests that the activation of the mammalian target of rapamycin (mTOR)/CD1 pathway by p38 mitogen-activated protein kinase (MAPK) might be the approach for AR and epidermal growth factor receptor (EGFR) cross-talk, leading to lung cancer development [79].